Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers

AOCS Group; AOCS Group

doi:10.1158/1055-9965.EPI-20-0739

Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers

AOCS Group, AOCS Group

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Background: Accumulating evidence suggests a relationship between endometrial cancer and ovarian cancer. Independent genome-wide association studies (GWAS) for endometrial cancer and ovarian cancer have identified 16 and 27 risk regions, respectively, four of which overlap between the two cancers. We aimed to identify joint endometrial and ovarian cancer risk loci by performing a meta-analysis of GWAS summary statistics from these two cancers. Methods: Using LDScore regression, we explored the genetic correlation between endometrial cancer and ovarian cancer. To identify loci associated with the risk of both cancers, we implemented a pipeline of statistical genetic analyses (i.e., inverse-variance meta-analysis, colocalization, and M-values) and performed analyses stratified by subtype. Candidate target genes were then prioritized using functional genomic data. Results: Genetic correlation analysis revealed significant genetic correlation between the two cancers (r_G = 0.43, P = 2.66 × 10^-5). We found seven loci associated with risk for both cancers (P_Bonferroni < 2.4 × 10^-9). In addition, four novel subgenome-wide regions at 7p22.2, 7q22.1, 9p12, and 11q13.3 were identified (P < 5 × 10^-7). Promoter-associated HiChIP chromatin loops from immortalized endometrium and ovarian cell lines and expression quantitative trait loci data highlighted candidate target genes for further investigation. Conclusions: Using cross-cancer GWAS meta-analysis, we have identified several joint endometrial and ovarian cancer risk loci and candidate target genes for future functional analysis. Impact: Our research highlights the shared genetic relationship between endometrial cancer and ovarian cancer. Further studies in larger sample sets are required to confirm our findings.

Original language	English
Pages (from-to)	217-228
Number of pages	12
Journal	Cancer Epidemiology Biomarkers and Prevention
Volume	30
Issue number	1
DOIs	https://doi.org/10.1158/1055-9965.EPI-20-0739
State	Published - 1 Jan 2021

Access to Document

10.1158/1055-9965.EPI-20-0739

Cite this

@article{ebc3ea2827b54c22b151da68704f7201,

title = "Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers",

abstract = "Background: Accumulating evidence suggests a relationship between endometrial cancer and ovarian cancer. Independent genome-wide association studies (GWAS) for endometrial cancer and ovarian cancer have identified 16 and 27 risk regions, respectively, four of which overlap between the two cancers. We aimed to identify joint endometrial and ovarian cancer risk loci by performing a meta-analysis of GWAS summary statistics from these two cancers. Methods: Using LDScore regression, we explored the genetic correlation between endometrial cancer and ovarian cancer. To identify loci associated with the risk of both cancers, we implemented a pipeline of statistical genetic analyses (i.e., inverse-variance meta-analysis, colocalization, and M-values) and performed analyses stratified by subtype. Candidate target genes were then prioritized using functional genomic data. Results: Genetic correlation analysis revealed significant genetic correlation between the two cancers (rG = 0.43, P = 2.66 × 10-5). We found seven loci associated with risk for both cancers (PBonferroni < 2.4 × 10-9). In addition, four novel subgenome-wide regions at 7p22.2, 7q22.1, 9p12, and 11q13.3 were identified (P < 5 × 10-7). Promoter-associated HiChIP chromatin loops from immortalized endometrium and ovarian cell lines and expression quantitative trait loci data highlighted candidate target genes for further investigation. Conclusions: Using cross-cancer GWAS meta-analysis, we have identified several joint endometrial and ovarian cancer risk loci and candidate target genes for future functional analysis. Impact: Our research highlights the shared genetic relationship between endometrial cancer and ovarian cancer. Further studies in larger sample sets are required to confirm our findings.",

author = "{AOCS Group} and {AOCS Group} and Glubb, {Dylan M.} and Thompson, {Deborah J.} and Aben, {Katja K.H.} and Ahmad Alsulimani and Frederic Amant and Daniela Annibali and John Attia and Aurelio Barricarte and Beckmann, {Matthias W.} and Andrew Berchuck and Marina Bermisheva and Bernardini, {Marcus Q.} and Katharina Bischof and Line Bjorge and Clara Bodelon and Brand, {Alison H.} and Brenton, {James D.} and Brinton, {Louise A.} and Fiona Bruinsma and Buchanan, {Daniel D.} and Stefanie Burghaus and Ralf Butzow and Hui Cai and Carney, {Michael E.} and Chanock, {Stephen J.} and Chu Chen and Chen, {Xiao Qing} and Zhihua Chen and Cook, {Linda S.} and Cunningham, {Julie M.} and {De Vivo}, Immaculata and Anna deFazio and Doherty, {Jennifer A.} and Thilo D{\"o}rk and {du Bois}, Andreas and Dunning, {Alison M.} and Matthias D{\"u}rst and Todd Edwards and Edwards, {Robert P.} and Ekici, {Arif B.} and Ailith Ewing and Fasching, {Peter A.} and Sarah Ferguson and Flanagan, {James M.} and Florentia Fostira and George Fountzilas and Friedenreich, {Christine M.} and Bo Gao and Rothstein, {Joseph H.} and Weiva Sieh",

note = "Funding Information: outside the submitted work. R. Klapdor reports nonfinancial support from Intuitive Surgical outside the submitted work. P. Kraft reports grants from NIH during the conduct of the study. M.C. Larson reports grants from Mayo Clinic during the conduct of the study and grants from Mayo Clinic outside the submitted work. L. Le Marchand reports grants from NCI (to author{\textquoteright}s institution) during the conduct of the study. D. Liang reports grants from Texas Southern University during the conduct of the study. V. McGuire reports grants from Stanford University during the conduct of the study. I.A. McNeish reports personal fees from Clovis Oncology, AstraZeneca, Tesaro, Roche, and Scancell and grants from AstraZeneca outside the submitted work. U. Menon reports other from Abcodia (shares in Abcodia given to her by UCL) outside the submitted work. F. Modugno reports grants from NCI and Department of Defense during the conduct of the study. H. Nevanlinna reports personal fees from AstraZeneca (honorarium) outside the submitted work. K. Odunsi reports funding from AstraZeneca and Tesaro Pharma. S. Orsulic reports grants from NIH/NCI, Department of Defense, and Ovarian Cancer Research Alliance outside the submitted work and has a patent for US010253368 issued and a patent for EU2908913 issued. T.-W. Park-Simon reports personal fees and other from Roche (advisory role, expert testimony, clinical trials, travel), AstraZeneca (advisory role, expert testimony, clinical trials, travel), Daichii (advisory role, expert testimony, clinical trials, travel), Tesaro (advisory role, expert testimony, clinical trials, travel), Novartis (advisory role, expert testimony, clinical trials, travel), Pfizer (advisory role, expert testimony, clinical trials, travel), Merck Sharp & Dohme (advisory role, expert testimony), and Lilly (advisory role, expert testimony, clinical trials, travel) outside the submitted work. C.L. Pearce reports grants from NIH and Department of Defense during the conduct of the study. J.H. Rothstein reports grants from NIH during the conduct of the study. A.J. Swerdlow reports grants from Breast Cancer Now, during the conduct of the study. L.C.V. Thomsen reports personal fees from Bayer and AstraZeneca, as well as other from AstraZeneca (financial support to a researcher-initiated trial) outside the submitted work. L. Titus reports grants from NIH/NCI during the conduct of the study. I. Vergote reports grants, personal fees, and other from Amgen (fees for consulting paid to author{\textquoteright}s university, corporate-sponsored research and accommodation, travel expenses) and Roche NV (fees for consulting paid to author{\textquoteright}s university, corporate-sponsored research and accommodation, travel expenses); personal fees and other from AstraZeneca NV/UK/Belux (fees for consulting paid to author{\textquoteright}s university, accommodation, travel expenses), Genmab A/S,B.V,US (fees for consulting paid to author{\textquoteright}s university and contracted research; KU Leuven), Merck Sharp & Dohme Belgium (fees for consulting paid to author{\textquoteright}s university and accommodation, travel expenses), Oncoinvent AS (fees for consulting paid to author{\textquoteright}s university and contracted research; KU Leuven), and Tesaro Inc./Bio GmbH (fees for consulting paid to author{\textquoteright}s university and accommodation, travel expenses); and personal fees (consulting paid to author{\textquoteright}s university) from Clovis Oncology Inc., Carrick Therapeutics, Debiopharm International SA, F. Hoffman-La Roche Ltd., GSK Pharmaceuticals NV, Immunogen Inc., Millennium Pharmaceuticals, Octimet Oncology NV, Pharmamar-Doctaforum Servicios SL, Sotio a.s., Deciphera Pharmaceuticals, and Verastem Oncology, outside the submitted work. P.M. Webb reports grants from National Health and Medical Research Council of Australia and Brisbane Women{\textquoteright}s Club during the conduct of the study, as well as grants from Astra Zeneca (to support an unrelated study of ovarian cancer) outside the submitted work. X. Wu reports grants from The University of Texas MD Anderson Cancer Center during the conduct of the study. D. Yannoukakos reports grants from AstraZeneca outside the submitted work. T.A. O{\textquoteright}Mara reports grants from National Health and Medical Council of Australia, Cancer Australia, Cure Cancer Australia, and CanToo Foundation during the conduct of the study. No disclosures were reported by the other authors. Funding Information: We thank ECAC and OCAC for provision of summary statistics to perform this study. We thank Siddhartha Kar for his helpful discussions and advice for designing the genetic analysis approaches. Full acknowledgments and funding for ECAC and OCAC can be found in the Supplementary Note. T.A. O{\textquoteright}Mara is supported by a National Health and Medical Research Council (NHMRC) Early Career Fellowship (APP1111246) and Investigator Fellowship (APP1173170). A.B. Spurdle is supported by an NHMRC Senior Research Fellowship (APP1061779) and Investigator Fellowship (APP1177524). This work was supported by a Cancer Australia PdCCRS Project Grant, funded by Cure Cancer Australia and the CanToo Foundation (#1138084), NHMRC project grants (APP1158083 and APP1109286), QIMR Berghofer Medical Research Institute Near Miss Funding, and a special purpose donation gratefully received from Sarah Stork. Funding Information: D.M. Glubb reports grants from National Health and Medical Research Council and QIMR Berghofer Medical Research Institute during the conduct of the study. D.J. Thompson reports other from Genomics plc (since the completion of the work in this paper, the author left the University of Cambridge and is now employed by Genomics plc) outside the submitted work. M.Q. Bernardini reports personal fees from AstraZeneca outside the submitted work. A. deFazio reports grants from National Health and Medical Research Council of Australia, Cancer Council New South Wales, Cancer Council Victoria, Cancer Council of South Australia, Cancer Council of Queensland, Cancer Council Tasmania, Cancer Foundation of Western Australia, and Cancer Institute New South Wales during the conduct of the study, as well as grants from AstraZeneca outside the submitted work. A. du Bois reports personal fees from AstraZeneca, GSK/Tesaro, Roche, Genmab/Seattle Genetics, Zodiac, and BIOCAD outside the submitted work. P.A. Fasching reports grants and personal fees from Novartis, as well as personal fees from Pfizer, Daiichi-Sankyo, AstraZeneca, Eisai, Merck Sharp & Dohme, Cepheid, Lilly, Pierre Fabre, and Seattle Genetics outside the submitted work. G. Fountzilas reports personal fees from Pfizer (advisory board), Sanofi (advisory board), Roche (advisory board), and AstraZeneca (honoraria) outside the submitted work and Genprex, Daiichi-Sankyo, and ARIAD stock ownership. G.G. Giles reports grants from National Health and Medical Research Council (paid to author{\textquoteright}s institution Cancer Council Victoria) during the conduct of the study. R. Glasspool reports grants from Sanofi-Aventis (some of the data used in this work were derived from clinical samples that were originally collected in an investigator initiated clinical trial supported by Sanofi-Aventis) during the conduct of the study. P. Harter reports grants and personal fees from AstraZeneca, Roche, and Tesaro/GSK; personal fees from Sotio, Immunogen, Stryker, Clovis, Zai Lab, Merck Sharp & Dohme, and Lilly; and grants from Genmab, European Union, DKH, and DFG outside the submitted work. M.E. Jones reports grants from Breast Cancer Now (research finding charity: program grant) during the conduct of the study. B.Y. Karlan reports grants from Ovarian Cancer Research Fund Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",

year = "2021",

month = jan,

day = "1",

doi = "10.1158/1055-9965.EPI-20-0739",

language = "English",

volume = "30",

pages = "217--228",

journal = "Cancer Epidemiology Biomarkers and Prevention",

issn = "1055-9965",

publisher = "American Association for Cancer Research Inc.",

number = "1",

}

TY - JOUR

T1 - Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers

AU - AOCS Group

AU - Glubb, Dylan M.

AU - Thompson, Deborah J.

AU - Aben, Katja K.H.

AU - Alsulimani, Ahmad

AU - Amant, Frederic

AU - Annibali, Daniela

AU - Attia, John

AU - Barricarte, Aurelio

AU - Beckmann, Matthias W.

AU - Berchuck, Andrew

AU - Bermisheva, Marina

AU - Bernardini, Marcus Q.

AU - Bischof, Katharina

AU - Bjorge, Line

AU - Bodelon, Clara

AU - Brand, Alison H.

AU - Brenton, James D.

AU - Brinton, Louise A.

AU - Bruinsma, Fiona

AU - Buchanan, Daniel D.

AU - Burghaus, Stefanie

AU - Butzow, Ralf

AU - Cai, Hui

AU - Carney, Michael E.

AU - Chanock, Stephen J.

AU - Chen, Chu

AU - Chen, Xiao Qing

AU - Chen, Zhihua

AU - Cook, Linda S.

AU - Cunningham, Julie M.

AU - De Vivo, Immaculata

AU - deFazio, Anna

AU - Doherty, Jennifer A.

AU - Dörk, Thilo

AU - du Bois, Andreas

AU - Dunning, Alison M.

AU - Dürst, Matthias

AU - Edwards, Todd

AU - Edwards, Robert P.

AU - Ekici, Arif B.

AU - Ewing, Ailith

AU - Fasching, Peter A.

AU - Ferguson, Sarah

AU - Flanagan, James M.

AU - Fostira, Florentia

AU - Fountzilas, George

AU - Friedenreich, Christine M.

AU - Gao, Bo

AU - Rothstein, Joseph H.

AU - Sieh, Weiva

N1 - Funding Information: outside the submitted work. R. Klapdor reports nonfinancial support from Intuitive Surgical outside the submitted work. P. Kraft reports grants from NIH during the conduct of the study. M.C. Larson reports grants from Mayo Clinic during the conduct of the study and grants from Mayo Clinic outside the submitted work. L. Le Marchand reports grants from NCI (to author’s institution) during the conduct of the study. D. Liang reports grants from Texas Southern University during the conduct of the study. V. McGuire reports grants from Stanford University during the conduct of the study. I.A. McNeish reports personal fees from Clovis Oncology, AstraZeneca, Tesaro, Roche, and Scancell and grants from AstraZeneca outside the submitted work. U. Menon reports other from Abcodia (shares in Abcodia given to her by UCL) outside the submitted work. F. Modugno reports grants from NCI and Department of Defense during the conduct of the study. H. Nevanlinna reports personal fees from AstraZeneca (honorarium) outside the submitted work. K. Odunsi reports funding from AstraZeneca and Tesaro Pharma. S. Orsulic reports grants from NIH/NCI, Department of Defense, and Ovarian Cancer Research Alliance outside the submitted work and has a patent for US010253368 issued and a patent for EU2908913 issued. T.-W. Park-Simon reports personal fees and other from Roche (advisory role, expert testimony, clinical trials, travel), AstraZeneca (advisory role, expert testimony, clinical trials, travel), Daichii (advisory role, expert testimony, clinical trials, travel), Tesaro (advisory role, expert testimony, clinical trials, travel), Novartis (advisory role, expert testimony, clinical trials, travel), Pfizer (advisory role, expert testimony, clinical trials, travel), Merck Sharp & Dohme (advisory role, expert testimony), and Lilly (advisory role, expert testimony, clinical trials, travel) outside the submitted work. C.L. Pearce reports grants from NIH and Department of Defense during the conduct of the study. J.H. Rothstein reports grants from NIH during the conduct of the study. A.J. Swerdlow reports grants from Breast Cancer Now, during the conduct of the study. L.C.V. Thomsen reports personal fees from Bayer and AstraZeneca, as well as other from AstraZeneca (financial support to a researcher-initiated trial) outside the submitted work. L. Titus reports grants from NIH/NCI during the conduct of the study. I. Vergote reports grants, personal fees, and other from Amgen (fees for consulting paid to author’s university, corporate-sponsored research and accommodation, travel expenses) and Roche NV (fees for consulting paid to author’s university, corporate-sponsored research and accommodation, travel expenses); personal fees and other from AstraZeneca NV/UK/Belux (fees for consulting paid to author’s university, accommodation, travel expenses), Genmab A/S,B.V,US (fees for consulting paid to author’s university and contracted research; KU Leuven), Merck Sharp & Dohme Belgium (fees for consulting paid to author’s university and accommodation, travel expenses), Oncoinvent AS (fees for consulting paid to author’s university and contracted research; KU Leuven), and Tesaro Inc./Bio GmbH (fees for consulting paid to author’s university and accommodation, travel expenses); and personal fees (consulting paid to author’s university) from Clovis Oncology Inc., Carrick Therapeutics, Debiopharm International SA, F. Hoffman-La Roche Ltd., GSK Pharmaceuticals NV, Immunogen Inc., Millennium Pharmaceuticals, Octimet Oncology NV, Pharmamar-Doctaforum Servicios SL, Sotio a.s., Deciphera Pharmaceuticals, and Verastem Oncology, outside the submitted work. P.M. Webb reports grants from National Health and Medical Research Council of Australia and Brisbane Women’s Club during the conduct of the study, as well as grants from Astra Zeneca (to support an unrelated study of ovarian cancer) outside the submitted work. X. Wu reports grants from The University of Texas MD Anderson Cancer Center during the conduct of the study. D. Yannoukakos reports grants from AstraZeneca outside the submitted work. T.A. O’Mara reports grants from National Health and Medical Council of Australia, Cancer Australia, Cure Cancer Australia, and CanToo Foundation during the conduct of the study. No disclosures were reported by the other authors. Funding Information: We thank ECAC and OCAC for provision of summary statistics to perform this study. We thank Siddhartha Kar for his helpful discussions and advice for designing the genetic analysis approaches. Full acknowledgments and funding for ECAC and OCAC can be found in the Supplementary Note. T.A. O’Mara is supported by a National Health and Medical Research Council (NHMRC) Early Career Fellowship (APP1111246) and Investigator Fellowship (APP1173170). A.B. Spurdle is supported by an NHMRC Senior Research Fellowship (APP1061779) and Investigator Fellowship (APP1177524). This work was supported by a Cancer Australia PdCCRS Project Grant, funded by Cure Cancer Australia and the CanToo Foundation (#1138084), NHMRC project grants (APP1158083 and APP1109286), QIMR Berghofer Medical Research Institute Near Miss Funding, and a special purpose donation gratefully received from Sarah Stork. Funding Information: D.M. Glubb reports grants from National Health and Medical Research Council and QIMR Berghofer Medical Research Institute during the conduct of the study. D.J. Thompson reports other from Genomics plc (since the completion of the work in this paper, the author left the University of Cambridge and is now employed by Genomics plc) outside the submitted work. M.Q. Bernardini reports personal fees from AstraZeneca outside the submitted work. A. deFazio reports grants from National Health and Medical Research Council of Australia, Cancer Council New South Wales, Cancer Council Victoria, Cancer Council of South Australia, Cancer Council of Queensland, Cancer Council Tasmania, Cancer Foundation of Western Australia, and Cancer Institute New South Wales during the conduct of the study, as well as grants from AstraZeneca outside the submitted work. A. du Bois reports personal fees from AstraZeneca, GSK/Tesaro, Roche, Genmab/Seattle Genetics, Zodiac, and BIOCAD outside the submitted work. P.A. Fasching reports grants and personal fees from Novartis, as well as personal fees from Pfizer, Daiichi-Sankyo, AstraZeneca, Eisai, Merck Sharp & Dohme, Cepheid, Lilly, Pierre Fabre, and Seattle Genetics outside the submitted work. G. Fountzilas reports personal fees from Pfizer (advisory board), Sanofi (advisory board), Roche (advisory board), and AstraZeneca (honoraria) outside the submitted work and Genprex, Daiichi-Sankyo, and ARIAD stock ownership. G.G. Giles reports grants from National Health and Medical Research Council (paid to author’s institution Cancer Council Victoria) during the conduct of the study. R. Glasspool reports grants from Sanofi-Aventis (some of the data used in this work were derived from clinical samples that were originally collected in an investigator initiated clinical trial supported by Sanofi-Aventis) during the conduct of the study. P. Harter reports grants and personal fees from AstraZeneca, Roche, and Tesaro/GSK; personal fees from Sotio, Immunogen, Stryker, Clovis, Zai Lab, Merck Sharp & Dohme, and Lilly; and grants from Genmab, European Union, DKH, and DFG outside the submitted work. M.E. Jones reports grants from Breast Cancer Now (research finding charity: program grant) during the conduct of the study. B.Y. Karlan reports grants from Ovarian Cancer Research Fund Publisher Copyright: © 2020 American Association for Cancer Research.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Background: Accumulating evidence suggests a relationship between endometrial cancer and ovarian cancer. Independent genome-wide association studies (GWAS) for endometrial cancer and ovarian cancer have identified 16 and 27 risk regions, respectively, four of which overlap between the two cancers. We aimed to identify joint endometrial and ovarian cancer risk loci by performing a meta-analysis of GWAS summary statistics from these two cancers. Methods: Using LDScore regression, we explored the genetic correlation between endometrial cancer and ovarian cancer. To identify loci associated with the risk of both cancers, we implemented a pipeline of statistical genetic analyses (i.e., inverse-variance meta-analysis, colocalization, and M-values) and performed analyses stratified by subtype. Candidate target genes were then prioritized using functional genomic data. Results: Genetic correlation analysis revealed significant genetic correlation between the two cancers (rG = 0.43, P = 2.66 × 10-5). We found seven loci associated with risk for both cancers (PBonferroni < 2.4 × 10-9). In addition, four novel subgenome-wide regions at 7p22.2, 7q22.1, 9p12, and 11q13.3 were identified (P < 5 × 10-7). Promoter-associated HiChIP chromatin loops from immortalized endometrium and ovarian cell lines and expression quantitative trait loci data highlighted candidate target genes for further investigation. Conclusions: Using cross-cancer GWAS meta-analysis, we have identified several joint endometrial and ovarian cancer risk loci and candidate target genes for future functional analysis. Impact: Our research highlights the shared genetic relationship between endometrial cancer and ovarian cancer. Further studies in larger sample sets are required to confirm our findings.

AB - Background: Accumulating evidence suggests a relationship between endometrial cancer and ovarian cancer. Independent genome-wide association studies (GWAS) for endometrial cancer and ovarian cancer have identified 16 and 27 risk regions, respectively, four of which overlap between the two cancers. We aimed to identify joint endometrial and ovarian cancer risk loci by performing a meta-analysis of GWAS summary statistics from these two cancers. Methods: Using LDScore regression, we explored the genetic correlation between endometrial cancer and ovarian cancer. To identify loci associated with the risk of both cancers, we implemented a pipeline of statistical genetic analyses (i.e., inverse-variance meta-analysis, colocalization, and M-values) and performed analyses stratified by subtype. Candidate target genes were then prioritized using functional genomic data. Results: Genetic correlation analysis revealed significant genetic correlation between the two cancers (rG = 0.43, P = 2.66 × 10-5). We found seven loci associated with risk for both cancers (PBonferroni < 2.4 × 10-9). In addition, four novel subgenome-wide regions at 7p22.2, 7q22.1, 9p12, and 11q13.3 were identified (P < 5 × 10-7). Promoter-associated HiChIP chromatin loops from immortalized endometrium and ovarian cell lines and expression quantitative trait loci data highlighted candidate target genes for further investigation. Conclusions: Using cross-cancer GWAS meta-analysis, we have identified several joint endometrial and ovarian cancer risk loci and candidate target genes for future functional analysis. Impact: Our research highlights the shared genetic relationship between endometrial cancer and ovarian cancer. Further studies in larger sample sets are required to confirm our findings.

UR - http://www.scopus.com/inward/record.url?scp=85122168882&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-20-0739

DO - 10.1158/1055-9965.EPI-20-0739

M3 - Article

C2 - 33144283

AN - SCOPUS:85122168882

SN - 1055-9965

VL - 30

SP - 217

EP - 228

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

IS - 1

ER -

Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers

Abstract

Access to Document

Fingerprint

Cite this